Recent Finacing
Recent Raise
Oryzon develops epigenetics-based small-molecule therapies targeting LSD1 for CNS disorders and oncology, advancing multiple Phase II programs (vafidemstat, iadademstat), biomarker platform, offices in Barcelona and US.
Focus Areas
Recent Investors
Valuation as of 10/27/2015
Total Raised
Funding rounds
Investors
See the team members at Oryzon Genomics SA.
